Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have been given an average recommendation of “Hold” by the seven analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $56.40.

Several research analysts recently issued reports on PSTV shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. D. Boral Capital reaffirmed a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. Finally, Wall Street Zen upgraded Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. L1 Global Manager Pty Ltd bought a new position in shares of Plus Therapeutics during the 4th quarter valued at $1,167,000. Geode Capital Management LLC boosted its position in Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after buying an additional 589,544 shares during the period. Jane Street Group LLC purchased a new stake in Plus Therapeutics during the fourth quarter valued at about $525,000. Virtu Financial LLC bought a new position in shares of Plus Therapeutics during the fourth quarter valued at about $254,000. Finally, State Street Corp grew its stake in shares of Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after buying an additional 127,000 shares during the last quarter. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Trading Down 2.6%

Shares of NASDAQ PSTV opened at $3.82 on Thursday. Plus Therapeutics has a 12 month low of $2.90 and a 12 month high of $23.42. The firm has a market capitalization of $26.28 million, a price-to-earnings ratio of -1.66 and a beta of 1.40. The business has a 50-day moving average of $5.28 and a 200-day moving average of $6.89.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.97 million. On average, analysts predict that Plus Therapeutics will post -3.76 earnings per share for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.